Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Kite sails into in vivo CAR-T space via $350M Interius buyout
Gilead has become the latest pharma to strengthen its in vivo credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics.
James Waldron
Aug 21, 2025 9:59am
After 'complete standstill,' biotech market reaches new normal
Aug 20, 2025 11:04am
Painted into a corner, Mural agrees to Xoma buyout
Aug 20, 2025 10:28am
Jazz pays Saniona $42.5M to add prospect to epilepsy ensemble
Aug 20, 2025 9:13am
VantAI plays matchmaker for Halda's RIPTACs in $1B deal
Aug 19, 2025 8:00am
RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
Aug 19, 2025 7:18am
